| Exon skipping oligomer conjugates for muscular dystrophy |
2023-7-05 |
2023-9-01 |
|
| Peptide oligonucleotide conjugates |
2023-5-18 |
2023-6-08 |
|
| Multiple exon skipping compositions for dmd |
2023-5-10 |
2023-6-01 |
|
| Cell-penetrating peptides for antisense delivery |
2023-4-25 |
2023-6-15 |
|
| Peptide Oligonucleotide Conjugates |
2023-4-06 |
2023-10-05 |
|
| Multiple Exon Skipping Compositions for DMD |
2023-3-30 |
2023-5-25 |
|
| Systemic administration of adeno-associated virus vector expressing sarcoglycan … |
2023-3-29 |
2023-4-27 |
|
| Phosphorodiamidate morpholino oligomer conjugates |
2023-3-16 |
2023-9-21 |
|
| Adeno-associated virus vectors for the treatment of rett syndrome |
2023-3-14 |
2023-5-19 |
|
| Antisense oligomer compounds |
2023-2-15 |
2023-4-12 |
|
| Adeno-associated virus vector administration for muscular dystrophies |
2023-1-10 |
2023-3-27 |
|
| Morpholino oligomers for treatment of peripheral myelin protein 22 related … |
2022-10-24 |
2023-7-01 |
|
| Exon skipping compositions for treating muscular dystrophy |
2022-10-13 |
2022-11-10 |
|
| Exon skipping oligomer conjugates for muscular dystrophy |
2022-10-13 |
2022-12-13 |
|
| Antisense oligonucleotides having one or more abasic units |
2022-9-28 |
2023-4-06 |
|
| Delivery of anitsense oligomers by mirror image peptides |
2022-9-01 |
2023-3-09 |
|
| Methods to analyze aav capsid proteins |
2022-7-25 |
2022-10-31 |
|
| Processes for preparing phosphorodiamidate morpholino oligomers |
2022-6-15 |
2023-2-16 |
|
| Production of recombinant aav vectors for treating muscular dystrophy |
2022-5-13 |
2022-11-24 |
|
| Exon skipping compositions for treating muscular dystrophy |
2022-5-11 |
2023-4-06 |
|
| Exon skipping oligomer conjugates for muscular dystrophy |
2022-5-04 |
2023-5-09 |
2023-5-09 |
| Treatment methods for muscular dystrophy |
2022-4-29 |
2022-11-03 |
|
| Exon skipping oligomer conjugates for muscular dystrophy |
2022-4-27 |
2023-4-13 |
|
| Exon skipping compositions for treating muscular dystrophy |
2022-4-11 |
2022-5-05 |
|
| Antisense oligomers and methods of using the same for treating diseases … |
2022-3-01 |
2022-6-02 |
|
| Compositions and methods for treating duchenne muscular dystrophy and related … |
2022-1-27 |
2022-3-01 |
|
| Oligonucleotides for treating expanded repeat diseases |
2022-1-27 |
2022-3-25 |
|
| Oligonucleotide analogues targeting human lmna |
2022-1-04 |
2022-3-23 |
|
| Compositions for treating muscular dystrophy |
2022-1-03 |
2022-12-22 |
|
| Compositions comprising exon skipping oligonucleotide conjugates for treating … |
2021-12-22 |
2022-6-30 |
|
| Antisense-induced exon2 inclusion in acid alpha-glucosidase |
2021-12-15 |
2022-6-02 |
|
| Suspension mode seed train development for adherent cells |
2021-12-09 |
2023-10-18 |
|
| Functionally-Modified Oligonucleotides And Subunits Thereof |
2021-11-10 |
2022-4-28 |
|
| Methods for treating muscular dystrophy with casimersin |
2021-10-20 |
2021-10-29 |
|
| Adeno-associated virus antibodies and fragments thereof |
2021-9-17 |
2022-2-03 |
|
| Processes for preparing oligomers |
2021-7-15 |
2021-11-11 |
|
| Antisense-induced exon2 inclusion in acid alpha-glucosidase |
2021-7-12 |
2021-10-21 |
|
| Peptide oligonucleotide conjugates |
2021-7-11 |
2021-8-31 |
|
| Conjugates of exon skipping oligomers for muscular dystrophy |
2021-7-06 |
2021-10-29 |
|
| Oligonucleotide analogues having modified intersubunit linkages and/or terminal … |
2021-6-17 |
2021-7-29 |
|
| ADENO-ASSOCIATED VIRUS ADMINISTRATION FOR MUSCULAR DYSTROPHY |
2021-6-15 |
2022-9-21 |
|
| Methods and compounds for treatment of lymphocyte-related diseases and … |
2021-4-30 |
2021-9-16 |
|
| Antisense-induced exon exclusion in type vii collagen |
2021-4-20 |
2021-9-09 |
|
| Antisense-induced exon exclusion in myostatin |
2021-4-15 |
2022-3-24 |
|
| Oligonucleotide analogues targeting human lmna |
2021-4-07 |
2021-7-26 |
|
| Exon-skipping oligomers for muscular dystrophy |
2021-2-16 |
2021-5-31 |
|
| Processes for preparing phosphorodiamidate morpholino oligomers |
2021-2-08 |
2022-10-27 |
|
| Compound and method for treating myotonic dystrophy |
2021-2-05 |
2022-1-06 |
|
| Designing antisense oligonucleotide delivery peptides by interpretable machine … |
2021-1-22 |
2021-12-16 |
|
| METHODS FOR ANALYZING AAV CAPSID PROTEINS |
2021-1-04 |
2022-4-06 |
|
| Modified antisense oligomers for exon inclusion in spinal muscular atrophy |
2020-12-25 |
2021-4-01 |
|
| Processes for preparing phosphorodiamidate morpholino oligomers |
2020-12-23 |
2022-4-14 |
|
| Compositions and methods for restoring and maintaining the dystrophin- … |
2020-12-15 |
2023-1-18 |
|
| COMPOSITIONS AND METHODS FOR RESTORING AND MAINTAINING DYSTROPHIN-ASSOCIATED … |
2020-12-15 |
2022-3-16 |
|
| Aav transfer cassette |
2020-10-16 |
2021-4-22 |
|
| Oligonucleotide analogues targeting human LMNA |
2020-9-17 |
2023-10-31 |
2023-10-31 |
| Phosphorodiamidate morpholino oligomer pharmaceutical compositions |
2020-7-28 |
2021-2-11 |
|
| Exon skipping oligomers for muscular dystrophy |
2020-7-28 |
2021-6-24 |
|
| Methods for treating muscular dystrophy |
2020-7-20 |
2021-1-14 |
|
| Methods for treating muscular dystrophy |
2020-6-18 |
2020-12-24 |
|
| Peptide oligonucleotide conjugates |
2020-5-07 |
2023-8-22 |
2023-8-22 |
| Compositions for treating muscular dystrophy |
2020-4-16 |
2020-10-22 |
|
| Methods for the treatment of muscular dystrophy |
2020-3-31 |
2020-4-24 |
|
| METHODS TO TREAT MUSCULAR DYSTROPHY |
2020-3-26 |
2021-10-20 |
|
| Exon skipping oligomer conjugates for muscular dystrophy |
2020-3-15 |
2020-4-30 |
|
| Antisense composition and method for treating muscle atrophy |
2020-3-10 |
2021-5-13 |
|
| Trimeric peptides for antisense delivery |
2019-7-29 |
2022-5-18 |
|
| EXON SKIP OLIGOMERS FOR MUSCULAR DYSTROPHY |
2019-7-26 |
2021-3-03 |
|
| Exon skipping oligomers and oligomer conjugates for muscular dystrophy |
2019-6-13 |
2021-4-28 |
|
| Exon skipping oligomers for muscular dystrophy |
2019-6-12 |
2022-6-22 |
|
| Exon skipping oligomers for muscular dystropy |
2019-6-12 |
2020-1-23 |
|
| Exon skipping oligomers and oligomer conjugates for muscular dystrophy |
2019-4-23 |
2021-4-08 |
|
| Compositions for enhancing transport of molecules into cells |
2019-4-09 |
2021-2-02 |
2021-2-02 |
| Boronic acid conjugates of oligonucleotide analogues |
2019-3-22 |
2019-4-11 |
|
| Antisense molecules and methods for treating pathologies |
2019-3-19 |
2020-9-22 |
2020-9-22 |
| Chimeric peptides for antisense delivery |
2019-3-15 |
2021-1-20 |
|
| Processes for preparing morpholino phosphorodiamidate oligomers |
2018-12-19 |
2018-12-28 |
|
| Pharmaceutical compositions of morpholino phosphorodiamidate oligomer |
2018-12-19 |
2018-12-28 |
|
| Induced exon inclusion in spinal muscle atrophy |
2018-12-12 |
2019-4-18 |
|
| Bicyclic peptide oligonucleotide conjugates |
2018-10-17 |
2020-9-02 |
|
| Combination therapies for treating muscular dystrophy |
2018-9-28 |
2020-8-05 |
|
| Combination therapies for treating muscular dystrophy |
2018-9-28 |
2020-8-06 |
|
| Combination therapies for treating muscular dystrophy |
2018-9-28 |
2020-8-13 |
|
| Processes for preparing phosphorodiamidate morpholino oligomers via fast-flow … |
2018-9-25 |
2023-9-13 |
2023-9-13 |
| Methods and compositions for manipulating translation of protein isoforms from … |
2018-9-11 |
2019-8-08 |
|
| methods to treat muscular dystrophy |
2018-8-31 |
2020-9-24 |
|
| DsRNA molecules comprising oligonucleotide analogs having modified intersubunit … |
2018-7-06 |
2021-7-27 |
2021-7-27 |
| Tissue specific peptide conjugates and methods |
2018-6-27 |
2018-11-08 |
|
| Oligonucleotide analogues having cationic bonds between subunits |
2018-1-25 |
2019-7-10 |
|
| OLIGOMERIC CONJUGATES FOR EXON LEAP FOR MUSCLE DYSTROPHY |
2017-12-18 |
2019-3-27 |
|
| OLIGOMERIC CONJUGATES FOR EXON LEAP FOR MUSCLE DYSTROPHY |
2017-12-18 |
2019-4-10 |
|
| OLIGOMERIC CONJUGATES FOR EXON LEAP FOR MUSCLE DYSTROPHY |
2017-12-18 |
2019-3-27 |
|
| Exon skipping oligomer conjugates for muscular dystrophy |
2017-12-13 |
2022-12-23 |
|
| Splice-region antisense composition and method |
2017-10-03 |
2018-8-23 |
|
| Antisense composition and method for treating muscle atrophy |
2017-9-29 |
2017-10-19 |
|
| Processes for preparing phosphorodiamidate morpholino oligomers |
2017-6-30 |
2019-9-26 |
|
| 포스포로디아미데이트 모르폴리노 올리고머의 제조 방법 |
2017-6-30 |
2019-2-20 |
|